Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-BBN-IRDye800CW PET/NIRF in Glioblastoma
NCT02910804Phase 1Unknown
- Sponsor
- Beijing Tiantan Hospital
- Start
- Nov 2015
- Primary completion
- Dec 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-BBN-IRDye800CW in glioblastoma (GBM), sponsored by Beijing Tiantan Hospital. Primary endpoints: Standardized Uptake Value at 1 year and Margin Assessment of Positive Tumors at 1 year. Status: unknown.
02
Drugs
68Ga-BBN-IRDye800CW
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02910804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02910804.